Sumatriptan intranasal (Paratek Pharmaceuticals)

鼻内用舒马普坦 (Paratek Pharmaceuticals)

Report date: 2025/05/26 20:01:03

Base Information

Drug NameSumatriptan intranasal (Paratek Pharmaceuticals)
Drug Alias NameOptiNose sumatriptanOnzetra XsailAVP-825
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1b (5-HT1b) receptor agonistsSerotonin 1d (5-HT1d) receptor agonists
TargetsSerotonin 1b (5-HT1b) receptorSerotonin 1d (5-HT1d) receptor
Therapy Area/IndicationsHeadacheMigraine Disorders
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/01/27
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesOptinose As
China Registration ClassN/A

Develop Information

Active CompaniesCurrax Pharmaceuticals Llc
Inactive CompaniesOptinose Us IncAvanir Pharmaceuticals Inc
Active IndicationsMigraine Disorders
Inactive IndicationsHeadache

Other Information

ATC CodeN/A
Related LinksN/A